• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Up0.22%

    Galena Biopharma, Inc. (GALE)

    1.49 Down 0.02(1.32%) Nov 27, 1:00PM EST
    ProfileGet Profile for:
    Galena Biopharma, Inc.
    4640 SW Macadam Avenue
    Suite 270
    Portland, OR 97239
    United States - Map
    Phone: 855-855-4253
    Fax: 503- 400-6611
    Website: http://www.galenabiopharma.com

    Index Membership:N/A
    Full Time Employees:57

    Business Summary 

    Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products include Abstral, a sublingual tablet that is used for the management of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting. The company’s lead product candidate, NeuVax (nelipepimut-S), is in Phase III clinical trials for the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with Herceptin for neoadjuvantly treated node positive and negative HER2 IHC 3+ patients not achieving a pathological complete response. It also develops GALE-301 (folate binding protein), which is in Phase IIa clinical trials for the prevention of recurrence in patients with ovarian and endometrial cancers; and GALE-401 (anagrelide controlled release), which is in a Phase 2 clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. Galena Biopharma, Inc. has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers in India and with Teva Pharmaceuticals in Israel. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Portland, Oregon.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Galena Biopharma, Inc.

    Corporate Governance 
    Galena Biopharma, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 9. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Mark W. Schwartz Ph.D., 60
    Chief Exec. Officer, Pres, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
    Mr. Ryan M. Dunlap CPA, 45
    Chief Financial Officer and VP
    Ms. Remy Bernarda MBA,
    Sr. VP of Investor Relations & Corp. Communications
    Ms. Patricia Murphy ,
    VP of Regulatory & Compliance
    Mr. Thomas J. Knapp J.D., 62
    Interim Gen. Counsel
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders